You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

RQ-PCR

Showing 1 - 25 of 1,845
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Reduced Dose Dasatinib in Chronic Phase Chronic Myeloid Leukemia

Recruiting
  • Chronic Myelocytic Leukemia
  • RQ-PCR(Real-time Quantitative Polymerase chain reaction) RNA Analysis
  • Seoul, Korea, Republic of
    Seoul St. Mary's Hospital
Nov 1, 2019

Asciminib RMP Study

Not yet recruiting
  • Chronic Myeloid Leukemia
  • Asciminib
  • (no location specified)
Jul 5, 2023

Acute Promyelocytic Leukemia Trial in Worldwide (Mylotarg, Arsenic Trioxide, All-trans retinoic acid)

Recruiting
  • Acute Promyelocytic Leukemia
  • Brussels, Belgium
  • +30 more
Aug 9, 2022

CML, Chronic Phase Trial in Harbin (Flumatinib, Imatinib)

Not yet recruiting
  • CML, Chronic Phase
  • Harbin, Heilongjiang, China
    Institute of Hematology and Oncology, Harbin The First Hospital
May 5, 2022

ACUTE LYMPHOBLASTIC LEUKEMIA Trial (Inotuzumab ozogamicin, ALLR3)

Not yet recruiting
  • ACUTE LYMPHOBLASTIC LEUKEMIA
  • (no location specified)
Feb 17, 2023

CML Trial in Ciudad Autonoma de Buenos Aire (Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment)

Recruiting
  • CML
  • Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment
  • Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, Argentina
    FUNDALEU
Jun 29, 2023

The Life After Stopping Tyrosine Kinase Inhibitors Study

Completed
  • Leukemia, Myeloid, Chronic
  • Imatinib (Stopping their TKI)
  • +3 more
  • San Francisco, California
  • +15 more
Jan 3, 2023

CML, Chronic Phase Trial in Harbin (Flumatinib mesylate tablets (400mg), Flumatinib mesylate tablets (600mg))

Recruiting
  • CML, Chronic Phase
  • Flumatinib mesylate tablets (400mg)
  • Flumatinib mesylate tablets (600mg)
  • Harbin, Hei Longjiang, China
    Institute of Hematology and Oncology, Harbin The First Hospital
Apr 28, 2022

COVID-19, Infectious Disease, Symptomatic COVID-19 Infection Laboratory-Confirmed Trial in United States (RQ-001, Placebo)

Recruiting
  • COVID-19
  • +3 more
  • RQ-001
  • Placebo
  • Cullman, Alabama
  • +8 more
Sep 28, 2023

Olverembatinib, Chronic Myeloid Leukemia, Chronic Phase, Tyrosine Kinase Inhibitors Trial in Shenzhen (olverembatinib)

Recruiting
  • Olverembatinib
  • +2 more
  • Shenzhen, Guangdong, China
    Shenzhen Second People's Hospital
Jul 26, 2022

Precursor Cell Lymphoblastic Leukemia Trial in Germany (Inotuzumab ozogamicin)

Recruiting
  • Precursor Cell Lymphoblastic Leukemia
  • Inotuzumab ozogamicin
  • Augsburg, Germany
  • +13 more
Oct 31, 2022

Acute,Leukemia, Lymphoid Trial in Tianjin (Dasatinib, prednisone, cyclophosphamide)

Completed
  • Acute,Leukemia, Lymphoid
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Aug 2, 2022

MRD-tailored Therapy in Newly Diagnosed Multiple Myeloma With

Not yet recruiting
  • Multiple Myeloma
  • Minimal Residual Disease
    • (no location specified)
    Nov 1, 2023

    Tissue Samples From Undergone Neck Dissection for Oral Cancer

    Withdrawn
    • Head and Neck Cancer
    • microarray analysis
    • +2 more
    • Philadelphia, Pennsylvania
      Abramson Cancer Center of the University of Pennsylvania
    Jan 29, 2019

    Flumatinib, Chronic Myeloid Leukemia, Chronic Phase, Imatinib Trial in Shenzhen (Flumatinib)

    Recruiting
    • Flumatinib
    • +2 more
    • Shenzhen, Guangdong, China
      The Second People's Hospital of Shenzhen
    Mar 15, 2022

    RWE of 1st Line Treatment With ATO/ATRA for Adult APL

    Recruiting
    • Promyelocytic Leukemia, Adult Acute
    • Evaluation of first line treatment with ATO/ATRA outcome
    • Caba, Argentina
    • +1 more
    Nov 9, 2021

    miR-155 Expression in Episodic and Chronic Migraine

    Recruiting
    • Migraine
    • +3 more
      • Pavia, Italy
        IRCCS Mondino Foundation
      Jun 7, 2023

      Acute Myeloid Leukemia, Adult Trial in La Plata, Caba (Evaluation of first line treatment with intensive treatment outcome in

      Recruiting
      • Acute Myeloid Leukemia, Adult
      • Evaluation of first line treatment with intensive treatment outcome in adult patients with AML.
      • La Plata, Buenos Aires, Argentina
      • +1 more
      Nov 9, 2021

      Relapsed Neuroblastoma Trial in Minsk (DNA vaccine, Salmonella oral vaccine, Lenalidomide)

      Recruiting
      • Relapsed Neuroblastoma
      • DNA vaccine
      • +2 more
      • Minsk, Minsk Region, Belarus
        Belarussian Research Center for Pediatric Oncology, Hematology a
      Mar 1, 2022

      CML, Chronic Phase, CML, Accelerated Phase Trial in Wuhan (HS-10382(Part 1: Dose escalation), HS-10382(Part 2: Dose expansion))

      Recruiting
      • CML, Chronic Phase
      • CML, Accelerated Phase
      • HS-10382(Part 1: Dose escalation)
      • HS-10382(Part 2: Dose expansion)
      • Wuhan, Hubei, China
        Union Hospital affiliated to Tongji Medical College of Huazhong
      Jan 12, 2023

      Mantle Cell Lymphoma Trial in Warszawa, Wroclaw (Obinutuzumab)

      Terminated
      • Mantle Cell Lymphoma
      • Warszawa, Poland
      • +1 more
      Dec 23, 2021

      Chronic Myelogenous Leukemia Trial in Canada, United States (Nilotinib)

      Completed
      Has Results
      • Chronic Myelogenous Leukemia
      • Fayetteville, Arkansas
      • +22 more
      Jun 29, 2021

      Acute Myeloid Leukemia (AML) Trial in Austria, Germany (Dasatinib, Cytarabine, Daunorubicin)

      Active, not recruiting
      • Acute Myeloid Leukemia (AML)
      • Innsbruck, Austria
      • +53 more
      Sep 19, 2022

      Chronic Myelogenous Leukemia Trial in Worldwide (Dasatinib)

      Active, not recruiting
      • Chronic Myelogenous Leukemia
      • Amman, Jordan
      • +4 more
      Jan 17, 2022

      Vaginal Discharge, Sexually Transmitted Diseases Trial (Health care practitioner is informed of POCT results for CT and NG,

      Not yet recruiting
      • Vaginal Discharge
      • Sexually Transmitted Diseases
      • Health care practitioner is informed of POCT results for CT and NG
      • +2 more
      • (no location specified)
      Jul 26, 2023